NCT00551044View on ClinicalTrials.gov

Bicalutamide Monotherapy Has Significant Quality of Life Benefits for Men With Advanced Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 31, 2003

Study Completion Date

August 31, 2005

Conditions
Prostatic Neoplasms
Interventions
DRUG

Bicalutamide

Bicalutamide 150mg once daily, oral administration, for 12 months

Trial Locations (1)

CH48 5PE

Wirral University Teaching Hospitals NHS Trust, Upton

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Wirral University Teaching Hospital NHS Trust

OTHER